(MENAFN- PR Newswire)
"David's unparalleled leadership and three decades of expertise in women's health uniquely position him to lead Kindbody into a bold new era of growth and innovation," said Linda Mintz, Chairperson of Kindbody's Board. "As reproductive healthcare takes center stage in the national conversation, there has never been a more exciting moment to expand Kindbody's impact and empower more patients on their family-building journeys. Under David's guidance, we are poised to redefine the future of fertility care-expanding access, advancing technology, and realizing our mission of accessible and affordable fertility care for all."
Prior to Kindbody, Stern served as Chief Executive Officer of Boston IVF for five years, leading one of the nation's largest and most respected fertility networks. Over the course of his distinguished three-decade career in the fertility and women's health industries, he has held several key leadership positions. Notably, as CEO of Symbiomix Therapeutics, he spearheaded the company's transition from development to the successful commercial launch of Solosec, culminating in its acquisition by Lupin Pharmaceuticals in 2017. Stern has also held senior executive roles at Merck Serono, where he served as Senior Vice President and Head of the Global Fertility Business Franchise, and at EMD Serono as Executive Vice President of Endocrinology within their biopharmaceutical division. His extensive experience further includes strategic leadership at Celmatix, Ohana, and OvaScience, where he was instrumental in building commercial teams, shaping corporate strategy, and expanding scientific partnerships across the women's healthcare landscape. Stern holds an MBA with a concentration in International Marketing and Management from the F.W. Olin Graduate School of Business at Babson College, as well as a Bachelor of Science degree in Biology from Brandeis University.
"I am truly honored to join a company that has set the standard for innovation and leadership in reproductive healthcare," said David Stern. "Kindbody's commitment to patient-centered care and its trailblazing model-as the only family-building benefits provider for employers that also operates its own network of clinics-is transforming the way people access fertility services. There has never been a more exciting time to be part of Kindbody's mission of accessible and affordable fertility care for all. I'm eager to build on the company's strong foundation of clinical excellence by strengthening our operational infrastructure and investing in the exceptional team that will drive our next chapter of growth and impact."
About Kindbody
Kindbody is the leading U.S. fertility clinic network and global family-building benefits provider for employers on a mission to make fertility care more affordable and accessible for all. Kindbody serves patients at 27 state-of-the-art signature clinics and IVF labs, 400+ partner clinics, and in 113 countries around the world. Trusted by more than 135 employers, Kindbody's physician-led model covers the full-spectrum of reproductive healthcare including fertility assessments, fertility preservation, genetic testing, IVF, donor and surrogacy services, adoption, postpartum care, and menopause support. Kindbody is the only fertility benefits provider that serves patients directly, delivering a seamless, integrated experience with superior health outcomes at lower cost. Recognized for technology innovation and industry leadership, Kindbody has been named to CNBC Disruptor 50, Fast Company's Brands that Matter, Forbes Best Startup Employers, Inc.'s Best In Business list of most admired companies, as well as Deloitte Technology Fast 500TM, which recognizes the fastest growing and most innovative technology companies in North America. Founded in 2018, Kindbody has raised more than $315 million in debt and equity funding from leading investors including Perceptive Advisors, JP Morgan Chase's Morgan Health, GV, RRE Ventures, Claritas Health Ventures, Rock Springs Capital, Distributed Ventures, Whatif Ventures and TQ Ventures. Visit . and follow us on Instagram and Linkedin .
Comments
No comment